Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Recruiting 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5Thoracic 2Sarcoma 1Head & Neck 1

Conditions

Breast Neoplasms 279Triple Negative Breast Neoplasms 146Neoplasm Metastasis 27Ovarian Neoplasms 23Carcinoma, Non-Small-Cell Lung 17Inflammatory Breast Neoplasms 15Pancreatic Neoplasms 12Neoplasms 11Endometrial Neoplasms 11Breast Neoplasms, Male 11Colorectal Neoplasms 8Carcinoma, Ductal, Breast 8Stomach Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Lung Neoplasms 7Prostatic Neoplasms 6Melanoma 6Fallopian Tube Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pathologic Complete Response 5HER2-positive Breast Cancer 5Carcinoma, Ovarian Epithelial 5Esophageal Neoplasms 4Carcinoma, Lobular 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Multiple Myeloma 3

Interventions

Trastuzumab 5Carboplatin 5Docetaxel 4pertuzumab 3Paclitaxel 3Cyclophosphamide 3pembrolizumab 2Epirubicin 2Doxorubicin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1taxane 1talazoparib 1sarilumab 1pyrotinib 1pirarubicin 1pexidartinib 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1durvalumab 1dostarlimab 1cemiplimab 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Pathologic Complete Response × Carboplatin × Breast × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Guangdong Provincial People's Hospital

Phase 2 Unknown
60 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡